Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic

Executive Summary

The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx

You may also be interested in...



FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation

The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation

FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation

The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation

Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches

SkyePharma has waived its 180-day exclusivity for a generic version of Elan's Naprelan (naproxen), clearing the way for approval of Andrx' generic version of the product, Andrx says

Related Content

UsernamePublicRestriction

Register

PS039739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel